119 related articles for article (PubMed ID: 36735514)
1. Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival.
Rabah NM; Jarmula J; Hamza O; Khan HA; Chakravarthy V; Habboub G; Wright JM; Steinmetz MP; Wright CH; Krishnaney AA
Neurosurgery; 2023 Jun; 92(6):1183-1191. PubMed ID: 36735514
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
3. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
4. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
5. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
[TBL] [Abstract][Full Text] [Related]
7. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.
Beca F; Sebastiao APM; Pareja F; Dessources K; Lozada JR; Geyer F; Selenica P; Zeizafoun N; Wen HY; Norton L; Brogi E; Weigelt B; Reis-Filho JS
Histopathology; 2020 Aug; 77(2):321-326. PubMed ID: 32043609
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.
Cejalvo JM; Pérez-Fidalgo JA; Ribas G; Burgués O; Mongort C; Alonso E; Ibarrola-Villava M; Bermejo B; Martínez MT; Cervantes A; Lluch A
Breast Cancer Res Treat; 2016 Nov; 160(1):69-77. PubMed ID: 27628192
[TBL] [Abstract][Full Text] [Related]
10. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
11. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Lefebvre C; Bachelot T; Filleron T; Pedrero M; Campone M; Soria JC; Massard C; Lévy C; Arnedos M; Lacroix-Triki M; Garrabey J; Boursin Y; Deloger M; Fu Y; Commo F; Scott V; Lacroix L; Dieci MV; Kamal M; Diéras V; Gonçalves A; Ferrerro JM; Romieu G; Vanlemmens L; Mouret Reynier MA; Théry JC; Le Du F; Guiu S; Dalenc F; Clapisson G; Bonnefoi H; Jimenez M; Le Tourneau C; André F
PLoS Med; 2016 Dec; 13(12):e1002201. PubMed ID: 28027327
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR
Mollon LE; Anderson EJ; Dean JL; Warholak TL; Aizer A; Platt EA; Tang DH; Davis LE
Clin Breast Cancer; 2020 Jun; 20(3):e232-e243. PubMed ID: 32234362
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
14. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.
Fujii T; Matsuda N; Kono M; Harano K; Chen H; Luthra R; Roy-Chowdhuri S; Sahin AA; Wathoo C; Joon AY; Tripathy D; Meric-Bernstam F; Ueno NT
Eur J Cancer; 2018 Jan; 89():64-71. PubMed ID: 29232568
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.
Erickson AW; Habbous S; Wright F; Lofters AK; Jerzak KJ; Das S
JAMA Oncol; 2021 Aug; 7(8):1220-1224. PubMed ID: 34081080
[TBL] [Abstract][Full Text] [Related]
16. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract][Full Text] [Related]
17. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
20. Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers.
Schleifman EB; Desai R; Spoerke JM; Xiao Y; Wong C; Abbas I; O'Brien C; Patel R; Sumiyoshi T; Fu L; Tam RN; Koeppen H; Wilson TR; Raja R; Hampton GM; Lackner MR
PLoS One; 2014; 9(2):e88401. PubMed ID: 24520381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]